Patient randomisations
Patient randomisations with suspected or proven COVID-19
Available interventions in 8 domains
Total patients
Patients with suspected or proven COVID-19
Active sites in Europe
European region numbers: updated 06 November 2024
REMAP-CAP
A Randomised, Embedded, Multi-factorial, Adaptive Platform trial for
Community-Acquired Pneumonia
The study
The Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) was conceived after the 2009 Influenza AH1N1 (“Swine flu”) outbreak. During that pandemic and previous ones, the research response has been largely absent. REMAP-CAP was set up as an Adaptive Platform Trial embedded in clinical care that allows multiple therapies to be evaluated at the same time under a master protocol. In Europe, the trial is currently running in 15 countries.